Glclav-LB 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus 60 million spores, designed to treat a broad spectrum of bacterial infections. Amoxycillin, a beta-lactam antibiotic, inhibits bacterial cell wall synthesis, leading to cell lysis and death, while Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by resistant bacteria, thereby enhancing its efficacy against beta-lactamase-producing strains. The inclusion of Lactobacillus, a probiotic, helps maintain and restore normal gut flora disrupted by antibiotic therapy, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Glclav-LB 625 is indicated for respiratory tract infections, urinary tract infections, skin and soft tissue infections, and other susceptible bacterial infections. It is essential to use this medication under medical supervision to ensure appropriate dosing and duration, minimizing the risk of resistance development. Patients with a history of hypersensitivity to penicillins or beta-lactamase inhibitors should avoid this medication. Common adverse effects may include gastrointestinal discomfort, nausea, and allergic reactions. This combination offers an effective therapeutic option by combining antibacterial potency with probiotic support to enhance patient outcomes during antibiotic treatment.